Table 2 First two therapeutic agents in the Dominantly Inherited Alzheimer Network trials unit
From: Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
Drug | Type | Mechanism of action biomarker | Downstream biomarkers | Exploratory biomarkers |
|---|---|---|---|---|
Solanezumab (Eli Lilly and Company) | Anti-Aβ antibody (soluble Aβ) | CSF total and free Aβ40 and Aβ42 | CSF tau, ptau181, vMRI | FDG-PET, fcMRI |
Gantenerumab (Roche) | Anti-Aβ antibody (aggregated Aβ) | PET amyloid imaging | CSF tau, ptau181, vMRI | FDG-PET, fcMRI |